Ryuji Takeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryuji Takeda has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Keiji Yoshikawa
Yoshikawa Eye Clinic, Tokyo, Japan
6 shared publicationsAkiyoshi Sawabe
5 shared publicationsTairo Kimura
Ueno Eye Clinic, Tokyo, Japan
5 shared publications- Akiyoshi Sawabe
Department of Applied Biological Chemistry, Faculty of Agriculture, Kindai University, Nara 631-8505, Japan
4 shared publications Hirotaka Suzumura
Suzumura Eye Clinic, Tokyo, Japan
4 shared publicationsSadao Komemushi
4 shared publications
Latest Publications
- Open Access
Interindividual Variability in Functional Food Clinical Trials: Statistical Challenges, Responder Phenotypes, and Implications for Precision Nutrition
Interindividual variability in response to dietary and functional food interventions is increasingly being recognized as a central issue in precision nutrition. However, individuals showing large pre–post changes are frequently classified as responders without adequately considering measurement error, within-person biological variability, regression to the mean, or distinction between the observed outcome variability and true heterogeneity in treatment effect. This review critically examines responder and non-responder concepts in functional food and dietary intervention trials, focusing on statistical interpretation, clinical trial design, biological determinants, metabolomics, metabotyping, multi-omics integration, and machine-learning approaches. We highlight the limitations of threshold-based responder classification, separate within-group significance testing, post hoc subgroup analyses, and high-dimensional predictive models without appropriate validation. Evidence from representative intervention studies is organized along a progression from retrospective responder classification and biological characterization to baseline predictor identification, predictive modeling, external validation, and prospective response-guided intervention. Particular attention is given to the distinction between explaining why individuals appeared to respond and predicting response before intervention. Based on the methodological and empirical evidence reviewed, we propose a structured hierarchy for responder research, ranging from descriptive heterogeneity to prospective response-guided intervention. The key challenge for precision nutrition is therefore not simply to identify who appeared to respond, but to determine whether heterogeneous responses are reproducible, treatment-specific, prospectively predictable, and useful for improving intervention selection. Moving from retrospective classification toward validated prospective prediction will be essential for translating responder research in functional foods into rigorous and clinically meaningful precision nutrition.
Open AccessInterindividual Variability in Functional Food Clinical Trials: Statistical Challenges, Responder Phenotypes, and Implications for Precision Nutrition
Interindividual variability in response to dietary and functional food interventions is increasingly being recognized as a central issue in precision nutrition. However, individuals showing large pre–post changes are frequently classified as responders without adequately considering measurement error, within-person biological variability, regression to the mean, or distinction between the observed outcome variability and true heterogeneity in treatment effect. This review critically examines responder and non-responder concepts in functional food and dietary intervention trials, focusing on statistical interpretation, clinical trial design, biological determinants, metabolomics, metabotyping, multi-omics integration, and machine-learning approaches. We highlight the limitations of threshold-based responder classification, separate within-group significance testing, post hoc subgroup analyses, and high-dimensional predictive models without appropriate validation. Evidence from representative intervention studies is organized along a progression from retrospective responder classification and biological characterization to baseline predictor identification, predictive modeling, external validation, and prospective response-guided intervention. Particular attention is given to the distinction between explaining why individuals appeared to respond and predicting response before intervention. Based on the methodological and empirical evidence reviewed, we propose a structured hierarchy for responder research, ranging from descriptive heterogeneity to prospective response-guided intervention. The key challenge for precision nutrition is therefore not simply to identify who appeared to respond, but to determine whether heterogeneous responses are reproducible, treatment-specific, prospectively predictable, and useful for improving intervention selection. Moving from retrospective classification toward validated prospective prediction will be essential for translating responder research in functional foods into rigorous and clinically meaningful precision nutrition.
- Open Access
Effects of Astaxanthin, Lutein, and Zeaxanthin on Eye–Hand Coordination and Smooth-Pursuit Eye Movement after Visual Display Terminal Operation in Healthy Subjects: A Randomized, Double-Blind Placebo-Controlled Intergroup Trial
(1) Background: The impairment of eye–hand coordination and smooth-pursuit eye movement caused by visual display terminal (VDT) operation is thought to impair daily living activities, for which no effective methods are currently known. On the other hand, various food ingredients, including astaxanthin, lutein, and zeaxanthin, are known to help improve the eye health of VDT operators. This study aimed to test the hypothesis that the combination of astaxanthin, lutein, and zeaxanthin can prevent the impairment of eye–hand coordination and smooth-pursuit eye movement caused by VDT operation. (2) Methods: We conducted a randomized, placebo-controlled, parallel-group clinical trial. Healthy subjects who regularly worked with VDTs were randomly assigned to the active and placebo groups. All of the subjects took soft capsules containing 6 mg of astaxanthin, 10 mg of lutein, and 2 mg of zeaxanthin or placebo soft capsules once daily for eight weeks. We evaluated the eye–hand coordination, smooth-pursuit eye movements, and macular pigment optical density (MPOD) at 0, two, four, and eight weeks after soft-capsule intake. (3) Results: The active group showed significantly improved eye–hand coordination after VDT operation at eight weeks. However, there was no clear improvement in the effect of the supplementation on smooth-pursuit eye movements. The active group also showed a significant increase in MPOD levels. (4) Conclusions: Consumption of a supplement containing astaxanthin, lutein, and zeaxanthin mitigates the decline of eye–hand coordination after VDT operation.
Open AccessEffects of Astaxanthin, Lutein, and Zeaxanthin on Eye–Hand Coordination and Smooth-Pursuit Eye Movement after Visual Display Terminal Operation in Healthy Subjects: A Randomized, Double-Blind Placebo-Controlled Intergroup Trial
(1) Background: The impairment of eye–hand coordination and smooth-pursuit eye movement caused by visual display terminal (VDT) operation is thought to impair daily living activities, for which no effective methods are currently known. On the other hand, various food ingredients, including astaxanthin, lutein, and zeaxanthin, are known to help improve the eye health of VDT operators. This study aimed to test the hypothesis that the combination of astaxanthin, lutein, and zeaxanthin can prevent the impairment of eye–hand coordination and smooth-pursuit eye movement caused by VDT operation. (2) Methods: We conducted a randomized, placebo-controlled, parallel-group clinical trial. Healthy subjects who regularly worked with VDTs were randomly assigned to the active and placebo groups. All of the subjects took soft capsules containing 6 mg of astaxanthin, 10 mg of lutein, and 2 mg of zeaxanthin or placebo soft capsules once daily for eight weeks. We evaluated the eye–hand coordination, smooth-pursuit eye movements, and macular pigment optical density (MPOD) at 0, two, four, and eight weeks after soft-capsule intake. (3) Results: The active group showed significantly improved eye–hand coordination after VDT operation at eight weeks. However, there was no clear improvement in the effect of the supplementation on smooth-pursuit eye movements. The active group also showed a significant increase in MPOD levels. (4) Conclusions: Consumption of a supplement containing astaxanthin, lutein, and zeaxanthin mitigates the decline of eye–hand coordination after VDT operation.
- Open Access
Skin-Beautifying Effects of Magnolol and Honokiol Glycosides
Glycosides have been synthesized using the starting materials magnolol (1) and honokiol (4), isolated from the Japanese white-bark magnolia, and their anti-aging effects on the skin (skin-beautifying effects) have been examined. The advanced glycation end-product (AGE) inhibitory activity test (anti-glycation test) and glycation induction model test, using human-derived dermal fibroblasts, TIG-110 cells, have been conducted to evaluate the anti-aging effects. The synthesized glycoside compounds, 5,5′-di(prop-2-en-1-yl)[1,1′-biphenyl]-2-hydroxy-2′-glucopyranoside (3a), 5,5′-di(prop-2-en-1-yl)[1,1′-biphenyl]-2,2′-diglucopyranoside (3b), 3′,5-di(prop-2-en-1-yl)[1,1′-biphenyl]-4′-hydroxy-2-glucopyranoside (6a) and 3′,5-di(prop-2-en-1-yl)[1,1′-biphenyl]-2,4′-diglucopyranoside (6b), have shown significant anti-glycation activities of less than 0.10 mM in IC50. The glycation induction model test with the fibroblasts, TIG-110 cells, demonstrates that the aforementioned glycosides significantly inhibit the decrease in cell viability. These newly synthesized glycoside compounds are expected to be used as cosmetic ingredients, health foods, and pharmaceutical ingredients, which have inhibitory effects against AGE formation.
Open AccessSkin-Beautifying Effects of Magnolol and Honokiol Glycosides
Glycosides have been synthesized using the starting materials magnolol (1) and honokiol (4), isolated from the Japanese white-bark magnolia, and their anti-aging effects on the skin (skin-beautifying effects) have been examined. The advanced glycation end-product (AGE) inhibitory activity test (anti-glycation test) and glycation induction model test, using human-derived dermal fibroblasts, TIG-110 cells, have been conducted to evaluate the anti-aging effects. The synthesized glycoside compounds, 5,5′-di(prop-2-en-1-yl)[1,1′-biphenyl]-2-hydroxy-2′-glucopyranoside (3a), 5,5′-di(prop-2-en-1-yl)[1,1′-biphenyl]-2,2′-diglucopyranoside (3b), 3′,5-di(prop-2-en-1-yl)[1,1′-biphenyl]-4′-hydroxy-2-glucopyranoside (6a) and 3′,5-di(prop-2-en-1-yl)[1,1′-biphenyl]-2,4′-diglucopyranoside (6b), have shown significant anti-glycation activities of less than 0.10 mM in IC50. The glycation induction model test with the fibroblasts, TIG-110 cells, demonstrates that the aforementioned glycosides significantly inhibit the decrease in cell viability. These newly synthesized glycoside compounds are expected to be used as cosmetic ingredients, health foods, and pharmaceutical ingredients, which have inhibitory effects against AGE formation.
- Open Access
Development of Evaluation Methods for Anti-Glycation Activity and Functional Ingredients Contained in Coriander and Fennel Seeds
Spices are known to have various physiological functions. We focused on the anti-glycation effects of spices, researched anti-glycation active ingredients in coriander (Coriandrum sativum L.) and fennel (Foeniculum vulgare) seeds, and conducted experiments using human skin-derived fibroblast TIG-110 cells as a model of glycation. We isolated 11 compounds from two spice seeds and found several substances that showed anti-glycation activity. A new compound (5,5′-diallyl-2,2′-diglucopyranosyl-3,3′-dimethoxy diphenyl ether) was isolated from fennel seeds and showed high anti-glycation activity with an IC50 value of 0.08 mM, thereby indicating a high anti-glycosylation activity. In this study, we established a glyoxal (GO)-induced glycation test method for human skin cells, confirmed the anti-glycation effect of spice seeds using this glycation induction model, and found that the exposure of TIG-110 human skin-derived fibroblast cells to GO reduced cell viability. The most stable conditions for cell viability were found to be a GO concentration of 1.25 mM and a culture time of 48 h. We evaluated extracts and isolates of spice seeds using this model as a model test for glycation induction. We conducted qualitative and quantitative analyses of carboxymethyl lysine (CML), a type of AGE, to determine the relationship between cell viability and AGEs. The relationship between cell viability and the amount of CML was correlated. Establishing a glycation induction model test using skin cells makes it possible to quickly screen extracts of natural ingredients in the future. Moreover, the results of this model showed that extracts of two spice seeds and their isolates have high anti-glycation activity, and they are expected to be used as cosmetics, health foods, and pharmaceutical ingredients.
Open AccessDevelopment of Evaluation Methods for Anti-Glycation Activity and Functional Ingredients Contained in Coriander and Fennel Seeds
Spices are known to have various physiological functions. We focused on the anti-glycation effects of spices, researched anti-glycation active ingredients in coriander (Coriandrum sativum L.) and fennel (Foeniculum vulgare) seeds, and conducted experiments using human skin-derived fibroblast TIG-110 cells as a model of glycation. We isolated 11 compounds from two spice seeds and found several substances that showed anti-glycation activity. A new compound (5,5′-diallyl-2,2′-diglucopyranosyl-3,3′-dimethoxy diphenyl ether) was isolated from fennel seeds and showed high anti-glycation activity with an IC50 value of 0.08 mM, thereby indicating a high anti-glycosylation activity. In this study, we established a glyoxal (GO)-induced glycation test method for human skin cells, confirmed the anti-glycation effect of spice seeds using this glycation induction model, and found that the exposure of TIG-110 human skin-derived fibroblast cells to GO reduced cell viability. The most stable conditions for cell viability were found to be a GO concentration of 1.25 mM and a culture time of 48 h. We evaluated extracts and isolates of spice seeds using this model as a model test for glycation induction. We conducted qualitative and quantitative analyses of carboxymethyl lysine (CML), a type of AGE, to determine the relationship between cell viability and AGEs. The relationship between cell viability and the amount of CML was correlated. Establishing a glycation induction model test using skin cells makes it possible to quickly screen extracts of natural ingredients in the future. Moreover, the results of this model showed that extracts of two spice seeds and their isolates have high anti-glycation activity, and they are expected to be used as cosmetics, health foods, and pharmaceutical ingredients.
- Open Access
- 1 July 2021
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 15, 2875-2883
Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
Purpose: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of <= 16 mmHg. Herein, we describe an additional post-hoc stratifying analysis of the possible differences in the effect of IOP-lowering and pulse rate (PR) after adjunctive Brim or Tim to PGA. Patients and Methods: This study included 128 subjects. Patients with NTG treated with PGA were stratified based on their baseline IOP. The changes in IOP from baseline and the effect of patient factors on IOP changes were investigated. Patients were stratified by age for investigation of their PR and blood pressure (BP). The change and the effect of patient factors on PR and BP were investigated. Results: After stratification analysis, in 52 eyes treated with Brim and 61 eyes with Tim with baseline IOP 12 <= IOP <= 16 mmHg, both eye drops lowered IOP significantly (P < 0.0001), and the IOP-lowering efficacy of Brim was non-inferior to that of Tim. However, in 9 Brim- and 6 Tim-treated eyes with baseline IOP of <12 mmHg, no statistically significant decrease in IOP was evident with either eye drop. In the Tim group, PR decreased significantly (P < 0.05) after stratification by age. Conclusion: The IOP-lowering efficacy of Brim was non-inferior to that of Tim after stratification by baseline IOP (12 <= IOP <= 16 mmHg). The discrepancy in the IOP-lowering effects of Brim and Tim observed in the previous study was thought to be related to enrolled subjects with low baseline IOP. PR decreased significantly in the Tim group even after age stratification. PR should be considered when selecting beta-blockers for glaucoma treatment.
- 1 July 2021
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 15, 2875-2883
Open AccessStratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
Purpose: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of <= 16 mmHg. Herein, we describe an additional post-hoc stratifying analysis of the possible differences in the effect of IOP-lowering and pulse rate (PR) after adjunctive Brim or Tim to PGA. Patients and Methods: This study included 128 subjects. Patients with NTG treated with PGA were stratified based on their baseline IOP. The changes in IOP from baseline and the effect of patient factors on IOP changes were investigated. Patients were stratified by age for investigation of their PR and blood pressure (BP). The change and the effect of patient factors on PR and BP were investigated. Results: After stratification analysis, in 52 eyes treated with Brim and 61 eyes with Tim with baseline IOP 12 <= IOP <= 16 mmHg, both eye drops lowered IOP significantly (P < 0.0001), and the IOP-lowering efficacy of Brim was non-inferior to that of Tim. However, in 9 Brim- and 6 Tim-treated eyes with baseline IOP of <12 mmHg, no statistically significant decrease in IOP was evident with either eye drop. In the Tim group, PR decreased significantly (P < 0.05) after stratification by age. Conclusion: The IOP-lowering efficacy of Brim was non-inferior to that of Tim after stratification by baseline IOP (12 <= IOP <= 16 mmHg). The discrepancy in the IOP-lowering effects of Brim and Tim observed in the previous study was thought to be related to enrolled subjects with low baseline IOP. PR decreased significantly in the Tim group even after age stratification. PR should be considered when selecting beta-blockers for glaucoma treatment.
- Open Access
Lactobacillus helveticus SBT2171 Alleviates Perennial Allergic Rhinitis in Japanese Adults by Suppressing Eosinophils: A Randomized, Double-Blind, Placebo-Controlled Study
This article examines the effects of fermented milk (FM) containing Lactobacillus helveticus SBT2171 (LH2171) on the subjective symptoms of individuals with mild and moderate perennial allergy. Two hundred subjects were divided into two groups and consumed FM containing LH2171 or placebo FM once per day for 16 weeks. The primary endpoints were defined as per the degree of nasal and ocular symptoms and difficulty in daily life as determined by the Japanese guidelines for allergy rhinitis and the Japanese allergic rhinitis standard quality of life questionnaire, respectively. The secondary endpoints included parameters related to allergic symptoms in the blood and nasal fluids, as well as the mental status. The severity of allergic rhinitis significantly improved in the LH2171 group compared to that in the placebo group. Additionally, the LH2171 group showed a significantly lower degree of “stuffy nose” (as per the diary survey) than the placebo group. Eosinophil counts in the nasal fluids and in the blood were significantly lower in the LH2171 group compared to the placebo group. Thus, the oral administration of FM containing LH2171 cells alleviated perennial allergic rhinitis in individuals with mild and moderate symptoms, possibly via suppression of eosinophils in both the blood and nasal fluids.
Open AccessLactobacillus helveticus SBT2171 Alleviates Perennial Allergic Rhinitis in Japanese Adults by Suppressing Eosinophils: A Randomized, Double-Blind, Placebo-Controlled Study
This article examines the effects of fermented milk (FM) containing Lactobacillus helveticus SBT2171 (LH2171) on the subjective symptoms of individuals with mild and moderate perennial allergy. Two hundred subjects were divided into two groups and consumed FM containing LH2171 or placebo FM once per day for 16 weeks. The primary endpoints were defined as per the degree of nasal and ocular symptoms and difficulty in daily life as determined by the Japanese guidelines for allergy rhinitis and the Japanese allergic rhinitis standard quality of life questionnaire, respectively. The secondary endpoints included parameters related to allergic symptoms in the blood and nasal fluids, as well as the mental status. The severity of allergic rhinitis significantly improved in the LH2171 group compared to that in the placebo group. Additionally, the LH2171 group showed a significantly lower degree of “stuffy nose” (as per the diary survey) than the placebo group. Eosinophil counts in the nasal fluids and in the blood were significantly lower in the LH2171 group compared to the placebo group. Thus, the oral administration of FM containing LH2171 cells alleviated perennial allergic rhinitis in individuals with mild and moderate symptoms, possibly via suppression of eosinophils in both the blood and nasal fluids.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 14, 213-219
The Effect of Brimonidine 0.1% on Disc Hemorrhage in Primary Open-Angle Glaucoma Patients
Background: This retrospective study evaluated the effect of adjunctive administration of brimonidine 0.1% on disc hemorrhage (DH) in patients with primary open-angle glaucoma or normal-tension glaucoma who were already treated with other anti-glaucoma drugs. Methods: Patients with DH, before adjunctive therapy with brimonidine, were enrolled. Subjects were excluded if their treatment regimen was changed within 1 year after initiation of adjunctive therapy with brimonidine. We investigated the frequency of DH and intraocular pressure (IOP). Both parameters were compared before and after adjunctive administration of brimonidine. Results: The frequency of DH before and after brimonidine administration was 0.67± 0.68 and 0.31± 0.72 times/year, respectively, with a significant decrease (P=0.01), and the mean IOP before and after brimonidine administration was 12.5± 1.9 and 11.2± 2.2 mmHg, respectively, (P=0.0006) with a significant reduction after adjunctive administration. Conclusion: The results of this study supported the hypothesis that the frequency of DH is reduced by brimonidine alongside lowering of IOP.
- 1 January 2020
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 14, 213-219
Open AccessThe Effect of Brimonidine 0.1% on Disc Hemorrhage in Primary Open-Angle Glaucoma Patients
Background: This retrospective study evaluated the effect of adjunctive administration of brimonidine 0.1% on disc hemorrhage (DH) in patients with primary open-angle glaucoma or normal-tension glaucoma who were already treated with other anti-glaucoma drugs. Methods: Patients with DH, before adjunctive therapy with brimonidine, were enrolled. Subjects were excluded if their treatment regimen was changed within 1 year after initiation of adjunctive therapy with brimonidine. We investigated the frequency of DH and intraocular pressure (IOP). Both parameters were compared before and after adjunctive administration of brimonidine. Results: The frequency of DH before and after brimonidine administration was 0.67± 0.68 and 0.31± 0.72 times/year, respectively, with a significant decrease (P=0.01), and the mean IOP before and after brimonidine administration was 12.5± 1.9 and 11.2± 2.2 mmHg, respectively, (P=0.0006) with a significant reduction after adjunctive administration. Conclusion: The results of this study supported the hypothesis that the frequency of DH is reduced by brimonidine alongside lowering of IOP.
- 1 December 2018
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 41, 47-51
Effect of crocetin on quality of sleep: A randomized, double-blind, placebo-controlled, crossover study
- 1 December 2018
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 41, 47-51
Effect of crocetin on quality of sleep: A randomized, double-blind, placebo-controlled, crossover study
- Open Access
- 1 August 2018
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 12, 1567-1577
Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy
Purpose: We investigated patient adherence and factors related to a newly introduced prostaglandin analog and timolol fixed-combination eye drops (PGTFC). Patients and methods: The Glaucoma Research on Adherence to fixed-Combination Eye drops in Japan (GRACE) study group performed a nationwide prospective questionnaire survey. Participants in this study were patients with glaucoma who were scheduled to receive any type of PGTFC for the first time. The participants answered a questionnaire on the day of PGTFC introduction and again at a return visit 4–6 weeks after PGTFC introduction. The physicians in charge were asked to complete a separate questionnaire on the day of PGTFC introduction. One of two leaflets was randomly delivered to each participant before the description of the PGTFC. One leaflet explained how to correctly instill the eye drops, and the other explained the clinical meaning of intraocular pressure reduction in addition to explaining how to correctly instill the eye drops. Nonadherence was defined as forgetting to instill the eye drops one or more times during the week before the return visit. Results: In total, 3,597 patients (age, 68.4±12.2 years) met the study protocol requirements. PGTFC introduction significantly reduced the number of antiglaucoma eye drops from 1.93±0.78 to 1.34±0.54 (PPConclusion: PGTFC significantly improved adherence and some of the factors that were significantly associated with adherence. Registration number: UMIN000013696
- 1 August 2018
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 12, 1567-1577
Open AccessChanges in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy
Purpose: We investigated patient adherence and factors related to a newly introduced prostaglandin analog and timolol fixed-combination eye drops (PGTFC). Patients and methods: The Glaucoma Research on Adherence to fixed-Combination Eye drops in Japan (GRACE) study group performed a nationwide prospective questionnaire survey. Participants in this study were patients with glaucoma who were scheduled to receive any type of PGTFC for the first time. The participants answered a questionnaire on the day of PGTFC introduction and again at a return visit 4–6 weeks after PGTFC introduction. The physicians in charge were asked to complete a separate questionnaire on the day of PGTFC introduction. One of two leaflets was randomly delivered to each participant before the description of the PGTFC. One leaflet explained how to correctly instill the eye drops, and the other explained the clinical meaning of intraocular pressure reduction in addition to explaining how to correctly instill the eye drops. Nonadherence was defined as forgetting to instill the eye drops one or more times during the week before the return visit. Results: In total, 3,597 patients (age, 68.4±12.2 years) met the study protocol requirements. PGTFC introduction significantly reduced the number of antiglaucoma eye drops from 1.93±0.78 to 1.34±0.54 (PPConclusion: PGTFC significantly improved adherence and some of the factors that were significantly associated with adherence. Registration number: UMIN000013696
- 12 January 2018
- Published by Springer Nature in International Ophthalmology
- Vol. 39  (2) , 375-383
A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan
Few reports have investigated the status of adherence in Japan on a large scale. We aimed to investigate the status of adherence to topical glaucoma treatment and its associated factors.
- 12 January 2018
- Published by Springer Nature in International Ophthalmology
- Vol. 39  (2) , 375-383
A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan
Few reports have investigated the status of adherence in Japan on a large scale. We aimed to investigate the status of adherence to topical glaucoma treatment and its associated factors.